The role of sex steroid hormones in benign prostatic hyperplasia

References

• Lephart ED. Review: anti-oxidant and anti-aging properties of equol in prostate health (BPH). Open J Endocr Metab Dis 2014;2014:1–12
   Google Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male 2015;18:112–17
   PubMed Web of Science ®Google Scholar
• Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011;82:184–99
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 2015;54:R15–29
   PubMed Web of Science ®Google Scholar
• Fukami M, Homma K, Hasegawa T, Ogata T. Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. Develop Dyn 2013;242:320–9
   PubMed Web of Science ®Google Scholar
• Mostaghel EA. Beyond T and DHT-novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci 2014;10:602
   PubMed Web of Science ®Google Scholar
• Azzouni F, Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology 2012;79:1197–205
   PubMed Web of Science ®Google Scholar
• Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. ClinCancer Res 2011;17:5844–9
   Google Scholar
• Prezioso D, Denis LJ, Klocker H, et al. Estrogens and aspects of prostate disease. Int J Urol 2007;14:1–16
   PubMed Web of Science ®Google Scholar
• Ebert T. Clinical experiences with testosterone therapy: prostate safety. Aging Male 2004;7:304–11
   PubMedGoogle Scholar
• Meuleman EJ, Legros J-J, Bouloux PM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male 2015;18:157–63
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016;19:64–9
   PubMed Web of Science ®Google Scholar
• Minnemann T, Schubert M, Minnemann T, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007;10:155–8
   PubMed Web of Science ®Google Scholar
• Wada N, Hashizume K, Matsumoto S, Kakizaki H. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study. Aging Male 2016;19:12–14
   PubMed Web of Science ®Google Scholar
• SwerdloffrsWang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003;6:207–11
   PubMedGoogle Scholar
• Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 2008;197:483–91
   PubMed Web of Science ®Google Scholar
• Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008;168:1416–24
   PubMed Web of Science ®Google Scholar
• Liao C-H, Li H-Y, Chung S-D, et al. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years. Aging Male 2012;15:28–33
   PubMed Web of Science ®Google Scholar
• Roehrborn C, Ray P. Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. Prostate Cancer Prostatic Dis 2006;9:432–8
   PubMed Web of Science ®Google Scholar
• Richard A, Rohrmann S, Zhang L, et al. Racial variation in sex steroid hormone concentration in black and white men: a meta‐analysis. Andrology 2014;2:428–35
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol 2013;138:10–16
   PubMed Web of Science ®Google Scholar
• Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostaticdihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10:149–54
   PubMed Web of Science ®Google Scholar
• Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol 2010;184:1040–4
   PubMed Web of Science ®Google Scholar
• Geller J, Albert J, Lopez D, et al. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J Clin Endocrinol Metab 1976;43:686–8
   PubMed Web of Science ®Google Scholar
• Monti S, Silverio F, Toscano V, et al. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). J Androl 1998;19:428–33
   PubMedGoogle Scholar
• Roberts RO, Jacobson DJ, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004;61:124–31
   PubMed Web of Science ®Google Scholar
• Usoro AJ, Obot AS, Ekaidem IS, et al. Serum testosterone, 17β-estradiol and PSA levels in subjects with prostate disorders. Indian J Clin Biochem 2015;30:59–65
   PubMedGoogle Scholar
• Sköldefors H, Blomstedt B, Carlström K. Serum hormone levels in benign prostatic hyperplasia. Scand J Urol Nephrol 1978;12:111–14
   PubMed Web of Science ®Google Scholar
• Royuela M, De Miguel M, Bethencourt F, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001;168:447–54
   PubMed Web of Science ®Google Scholar
• Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61:2–7
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin AA, Haider A, Gooren L. Effects of testosterone on the lower urinary tract go beyond the prostate: new insights, new treatment options. Arab J Urol 2011;9:147–52
   PubMedGoogle Scholar
• Claus S, Wrenger M, Senge T, Schulze H. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res 1993;21:305–8
   PubMedGoogle Scholar
• Briganti A, Capitanio U, Suardi N, et al. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl 2009;8:865–71
   Web of Science ®Google Scholar
• Battikhi M. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients. Prostate Cancer Prostatic Dis 2003;6:256–60
   PubMed Web of Science ®Google Scholar
• Trumble BC, Stieglitz J, Rodriguez DE, et al. Challenging the inevitability of prostate enlargement: low levels of benign prostatic hyperplasia amongtsimane forager-horticulturalists. J Gerontol Series A: Biol Sci and Med Sci 2015;70:glv051
   Web of Science ®Google Scholar
• Mustafa M, Horuz R, Celik M, Kucukcan A. Is there an association between serum prostate-specific antigen values and serum testosterone levels in healthy men? Korean J Urol 2014;55:465–9
   PubMedGoogle Scholar
• Alsharef M, Kahie A, Conradie M, et al. Association between low serum free testosterone and adverse prognostic factors in men diagnosed with prostate cancer in KwaZulu-Natal. S Afr J Surg 2012;50:40–42
   PubMed Web of Science ®Google Scholar
• Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115–23
   PubMed Web of Science ®Google Scholar
• Haghsheno M-A, Mellström D, Peeker R, et al. Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement. Scand J Urol 2015;49:155–61
   PubMed Web of Science ®Google Scholar
• Pak TR, Chung WC, Lund TD, et al. The androgen metabolite, 5alpha-androstane-3beta, 17beta-diol (3betaAdiol), is a potent modulator of estrogenreceptor-beta1-mediated gene transcription in neuronal cells. Endocrinology 2005;146:147–55
   PubMed Web of Science ®Google Scholar
• McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. Proc Natl Acad Sci 2010;107:3123–8
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Cimino L, et al. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male 2016;19:34–9
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metabol 2001;86:724–31
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Plas E, Schatzl G, et al. Association of DHEA-S and estradiol serum levels to symptoms of aging men. Aging Male 2002;5:233–8
   PubMedGoogle Scholar